Abstract
Arbovirus emergence and epidemic potential, as approximated by the vectorial capacity formula, depends on several host and vector parameters including vector intrinsic ability to transmit the pathogen. Such ability, called vector competence is influenced by biotic (e.g. virus and vector genotype) and abiotic (e.g. temperature). Vector competence is often evaluated as a qualitative phenotype although it is a multistep, time-dependent, quantitative phenotype. Combination of experimental and modelling approaches can i) capture intra-vector dynamics of arboviral infection and ii) use data to estimate arbovirus epidemic potential. Here, we measured individual Aedes albopictus (Lyon, France) mosquitoes infection, dissemination, and transmission rate upon oral exposure to chikungunya virus (CHIKV, La Reunion Island isolate) at eleven time-points from day 2 to day 20 post-exposure (dpe) for a range of CHIKV infectious doses spanning human viremia. Statistical modelisation indicates an explosive CHIKV intra-vector dynamics mainly due to an absence of dissemination barrier with 100% of the infected mosquitoes ultimately exhibiting a disseminated infection regardless of the viral dose. Transmission rate data revealed a time and dose-dependent but overall weak transmission barrier with individuals transmitting as soon as 2 dpe and >50% infectious mosquitoes at 6 dpe for the highest dose. Epidemiological simulations conducted with an Agent-Based Model based on experimental intra-vector dynamics data showed that even at low mosquito biting rates, CHIKV triggers explosive outbreaks. Together, this reveals the high epidemic potential of this CHIKV isolate with this French metropolitan population of Aedes albopictus.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by IDEX Lyon scientific breakthrough project, Micro-Be-Have
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
